Malignant Histiocytosis With PD-L1 Expression-Dramatic Response to Nivolumab

Mayo Clin Proc. 2022 Jul;97(7):1401-1403. doi: 10.1016/j.mayocp.2022.05.012.
No abstract available

Publication types

  • Letter

MeSH terms

  • B7-H1 Antigen
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Histiocytic Sarcoma*
  • Humans
  • Lung Neoplasms* / pathology
  • Nivolumab / therapeutic use

Substances

  • B7-H1 Antigen
  • Nivolumab